LoadingLoadingLoadingThe quick read
Latest quote·Oct 12
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNeither. Revelation Biosciences Inc (REVB) insiders filed no open-market purchases or sales in the 90 days to Oct 18, 2026, according to SEC Form 4 filings.
None. No member of Congress disclosed a REVB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
2 funds hold a position.
No tracked top-trader positions in REVB right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 7, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.83 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 7, 2026 | -$0.87 / -$0.83Alpha Vantage | -4.82% miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$2.71 / -$1.15Alpha Vantage | -135.65% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 26, 2026 | -$1.65 / -$1.41Alpha Vantage | -17.02% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$7.08 / -$5.34Alpha Vantage | -32.58% miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$7.01 / -$4.46Alpha Vantage | -57.17% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 8, 2025 | -$25.32 / -$82.56Alpha Vantage | +69.33% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 6, 2025 | -$4.98 / -$10.32Alpha Vantage | +51.74% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 8, 2024 | -$161.28 / -$545.28Alpha Vantage | +70.42% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Fairly priced and running thin margins.
Valuation
Quality
Growth
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
